agenda
COVERING ALL THE IMPORTANT TOPICS
Amsterdam, 21 - 23 March 2023
Schedule
Create your personal agenda –check the favourite icon
Mar 218:55
Conference pass
Chair's Remarks
Keynotes
Ana Plata, Global Pricing Head, AstraZeneca
Mar 219:00
Conference pass
Patient perspective in decision making
Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, The Janssen Pharmaceutical Companies of Johnson & Johnson
Mar 219:20
Conference pass
The wizardry of market archetypes to uplift your access strategy in the EU
Keynotes
Alberto Briones, Senior Consultant, Lifescience Dynamics
Mar 219:40
Conference pass
Panel Discussion: Exploring the use of Access Operating Models: A ‘new’ model for industry?
Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, The Janssen Pharmaceutical Companies of Johnson & Johnson
Alexander Bastian, VP Value & Market Access, A.M. Pharma
Sandro Cesaro, Head of Europe Market Access & Pricing, Astrazeneca
Sally Chung, VP, Head of Market Access & Pricing Europe, GSK
Mar 2111:20
Conference pass
Chair's Remarks
Market Access and Pricing
Sandro Cesaro, Head of Europe Market Access & Pricing, Astrazeneca
Mar 2111:20
Conference pass
Chair's Remarks
Rare Diseases
Linda McNamara, Senior Director, Payer Value and Patient Access, Kyowa Kirin GmbH
Mar 2111:20
Conference pass
Chair's Remarrks
Advanced Therapies
Victor Maertens, Government Affairs Manager, EUCOPE
Mar 2111:20
Conference pass
Chair's Remarks
Big Data and Digital Health
Fausto Artico, Global R&D Tech Head of Innovation & Data Science, GSK
Mar 2111:20
Conference pass
Chair's Remarks
HTA
Marcus Droege, Vice President, Global Value & Market Access, Passage Bio
Mar 2111:25
Conference pass
Evidence planning for reimbursement of rare disease therapies
Market Access and Pricing
Simon Shohet, Market Access, Amicus Therapeutics
Mar 2111:25
Conference pass
Finding and treating patients with rare diseases – legislation in Germany
Rare Diseases
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Mar 2111:25
Conference pass
Should appraisal belong to HTA?
HTA
Goedele Van Haasteren, Staff Member, Swiss Federal Office of Public Health
Mar 2111:45
Conference pass
Stakeholder Validation of Evidence Generation Plans (EGPs) to Achieve Optimal Access
Evidence
Priti Jhingran, VP, Evidence Strategy, Genesis Research
Mar 2111:45
Conference pass
What’s the state of market access performance tracking in 2023?
Market Access and Pricing
Thomas Gilboy, Product Owner, Access Infinity
Mar 2111:45
Conference pass
Priority medicines: do we need a new organisation of the EU pharmaceutical market, and which one?
Rare Diseases
Francois Houyez, Treatment Information And Access Director, Health Policy Advisor, EURORDIS
Mar 2111:45
Conference pass
Cell and gene therapies – how high can prices go?
Advanced Therapies
David Carr, Senior Director of Global Pricing & Market Access, PRECISIONadvisors
Richard Macaulay, Vice President, PRECISIONadvisors
Mar 2111:45
Conference pass
EU HTA: will it facilitate or hinder patient access to new medicines?
HTA
Graham Foxon, Managing Director, Remap Consulting
Mar 2112:05
Conference pass
Does target trial emulation or quantitative bias analysis help the acceptance of real-world data external control arms?
Evidence
Sreeram Ramagopalan, Global Head Real-World Evidence (Market Access), Roche
Mar 2112:05
Conference pass
Different models of access for innovative products – a European Overview
Market Access and Pricing
Ad Antonisse, Director Market Access & External Affairs, AstraZeneca BV
Mar 2112:05
Conference pass
‘Research ready’ rare disease patient communities
Rare Diseases
Kirsty Hoyle, Chief Executive Officer, Metabolic Support UK
Mar 2112:05
Conference pass
The role of Market Access & Pricing in early development
Advanced Therapies
Ana Filipa Fonseca, Global Value & Access Director - Early Assets, Radioligand Therapy, Novartis
Mar 2112:05
Conference pass
How you enable actions on any kind of entity in complex eco-systems?
Big Data and Digital Health
Fausto Artico, Global R&D Tech Head of Innovation & Data Science, GSK
Mar 2112:05
Conference pass
The EU HTA Implications for Companies – What to Prepare for 2025
HTA
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 2112:25
Conference pass
Bridging the evidence gap between market access and improved healthcare outcomes: An RWE methodology for comparative uptake tracking in severe asthma
Evidence
Mar 2112:25
Conference pass
The top 10 Evidence Pricing Access challenges in oncology and immunology 2023-30 …… and how to overcome them
Market Access and Pricing
Chris Teale, SVP Market Access, Ipsos Market Access
Mar 2112:25
Conference pass
Yes! The patient as a key decision maker in gene therapy
Rare Diseases
Sophie Schmitz, Managing Partner, Partners4Access
Mar 2112:25
Conference pass
Common frustrations in integrated access planning and how can we overcome them?
Advanced Therapies
Mar 2112:25
Conference pass
EU JCA: Is it worth the W.A.I.T?
HTA
Jürgen Wasem, Professor for Health Services and Management, University Duisburg Essen
Mar 2113:55
Conference pass
Roundtables
Keynotes
Roundtable 01: Examining the barriers and the solutions to access to medicines for patients with rare diseases
Sandrine Ruiz, Global Market Access Manager, Immunocore Ltd
Roundtable 02: Patient reported data as part of the market access decision process
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Roundtable 03: What are the barriers to integrated (HEOR, Access, Development, Pricing) access planning? And how can we overcome them?
Roundtable 04: Freedom of choice and pharmaceutical regulation: How does it fit together?
Joerg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Sybille Riou, Global Market Access Manager, Miltenyi Biotec
Roundtable 05: Convincing payers on the prospect and advantages on paying for preventative health
Navin Sewak, Global Market Access Director, ViiV Healthcare
Roundtable 06: Drug shortages in Europe: identifying causes and finding potential solutions
Linda klein Holkenborg, Medical Advisor, CZ
Anke Pisters-van Roy, MD, CZ
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, CZ
Roundtable 07: Managed-Entry Agreements – differences between countries
Iselin Dahlen Syversen, Head of Department New Methods, Sykehusinnkjøp HF
Cecilie Astrup, Health economist, Amgros I/S
Roundtable 08: Value strategy – balancing label and access expectations
Nadia Kaskure, Value Strategy Lead, Novo Nordisk
Roundtable 09: Equity pricing: from concept to implementation’
Karen Eryou, Head, Industry Engagement, Access to Medicine Foundation
Herve Lilliu, Chief Executive Officer, Inbeeo
Ana Plata, Global Pricing Head, AstraZeneca
Roundtable 10: Vaccine approval and reimbursement: What are the challenges faced by vaccines for approval and reimbursement compared to pharmaceuticals and what can the pharmaceutical industry do to expedite uptake?
Roundtable 11: Realistic planning for P&MA data support in the EU
Roundtable 12: EU Joint HTA Readiness : How are you and your teams preparing for the upcoming change in 2025? ,Come join us and your industry peers at this roundtable discussion on readiness for EU Joint HTA.
Roundtable 13: Access beyond reimbursement - Enabling healthcare systems to better serve those in need
Harblas Ahir, Global Market Access, MSD
Roundtable 14: Trial diversity, equality and inclusion: what are the learnings and implications for access and value?
Wyatt Gotbetter, SVP Access Consulting, Parexel
Roundtable 15: Paid early access in Europe – Is it needed, and what should it look like?
Tom Kelly, Associate Director, Dolon
Mar 2114:50
Conference pass
Chair's Remarks
Evidence
Elena Panitti, Global Head Real World Evidence Excellence, Novartis
Mar 2114:50
Conference pass
Chair's Remarks
Market Access and Pricing
Harblas Ahir, Global Market Access, MSD
Mar 2114:50
Conference pass
Chair's Remarks
Rare Diseases
Marie-Sharmila Blandino, Global Integrated Access Strategy Lead at Amgen and Vice-Chair of EFPIA Oncology Platform, Amgen
Mar 2114:50
Conference pass
Chair's Remarks
Advanced Therapies
Lisette Kaskens, Director Market Access for Europe, Latam and Canada, Ferring Pharmaceuticals
Mar 2114:50
Conference pass
Chair's Remarks
Big Data and Digital Health
Shrividya Iyer, Executive Director, Global RWE & US HEOR, Eisai
Mar 2114:50
Conference pass
Chair's Remarks
HTA
Astrid Buys, Global Head of Tenders & Pricing, Bavarian Nordic A/S
Mar 2114:55
Conference pass
RCT duplicate: implications for industry
Evidence
Melvin Olson, Global Head Integrated Evidence Strategy and Innovation, Novartis
Mar 2114:55
Conference pass
Patient centricity in value and price assessment
Market Access and Pricing
Mata Charokopou, Global Head of Access, Price & Evidence, UCB
Mar 2114:55
Conference pass
Orphan-drugs incentives to secure patient access to innovation
Rare Diseases
Philippe Ghyssels, VP Corporate and Global Public Affairs, IPSEN
Mar 2114:55
Conference pass
Development strategies for advanced therapies for optimal patient outcomes
Advanced Therapies
Nuno Prego Ramos, Chief Executive Officer, cellmabs
Mar 2114:55
Conference pass
Use of Real-World Data in HTA Decisions
Big Data and Digital Health
Madhu Kabra, Global Director HEOR, MKGlobal
Mar 2114:55
Conference pass
Emerging Issues for HTA – EU HTA Regulations. What about the next scenario
HTA
Marco Marchetti, Director of Health Technology Assessment Unit, National Agency for Regional Care Services, Agenzia Nazionale per i Servizi Sanitari Regionali- Agenas
Mar 2115:15
Conference pass
Instant real-world evidence using automated analytical platforms such as Livingstone® : possible paradigm shift in healthcare intelligence and evaluation
Evidence
Mar 2115:15
Conference pass
The integration of digital in the payer evidence strategy
Market Access and Pricing
Sabina Heinz, Senior Principal Market Access, Ipsos Healthcare
Andy Ballantyne, VP Market Access, Ipsos Healthcare
Mar 2115:15
Conference pass
The Evolving HTA landscape in Saudi Arabia: A new era of opportunity for high-cost therapies
Rare Diseases
Lavni Varyani, Founder, Pharma BP DMCC
Mar 2115:15
Conference pass
How can value based contracting overcome ATMP pricing and market access challenges to ensure successful commercial launch?
Advanced Therapies
Mark Chalmers, Partner, Life Sciences Commercial Access, EY
Mar 2115:15
Conference pass
The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data
Big Data and Digital Health
Friso Coerts, Market Access & HTA Manager, Pfizer
Mar 2115:15
Conference pass
Divergent European HTA outcomes – how do we manage this challenge to European market access going forwards?
HTA
Andrew Mumford, Chief Executive Officer, Initiate Consultants
Adelaide Shaw, Market Access Consultant, Initiate Consultants
Mar 2115:35
Conference pass
Developing and implementing an approach to using RWE in health technology assessment
Evidence
Pall Jonsson, Programme director for Data, National Institute for Health & Care Excellence (NICE)
Mar 2115:35
Conference pass
Aligning decision uncertainty and risk-sharing
Advanced Therapies
Hans Severens, Scientific adviser, Severens HTA consultancy
Mar 2115:35
Conference pass
Joint HTA – European and local perspectives
HTA
Peny Retsa, Market Access and External Relations Director, AbbVie
Mar 2116:25
Conference pass
Chair's Remarks
Evidence
Maria Kubin, Vice President of Global Market Access, Bayer Healthcare Ag
Mar 2116:25
Conference pass
Chair's Remarks
Market Access and Pricing
Nadia Benhadi, Eu Market Access And Pricing Director, GlaxoSmithKline
Mar 2116:25
Conference pass
Chair's Remarks
Rare Diseases
Philippe Ghyssels, VP Corporate and Global Public Affairs, IPSEN
Mar 2116:25
Conference pass
Chair's Remarks
Advanced Therapies
Hannah Kurth, Market Access and Pricing Expert, Independent
Mar 2116:25
Conference pass
Chair's Remarks
Big Data and Digital Health
Mata Charokopou, Global Head of Access, Price & Evidence, UCB
Mar 2116:25
Conference pass
Chair's Remarks
HTA
Denise Globe, Head Global Health Economics and Outcomes Research Center of Excellence, Gilead Sciences
Mar 2116:30
Conference pass
Use of patient registries for collecting real world evidence for decision makers
Evidence
Wim Goettsch, Associate Professor of HTA, Utrecht Centre for Pharmaceutical Policy and Regulation
Mar 2116:30
Conference pass
Value-Based versus Cost-Plus Pricing: shared experience from Payer Interactions
Market Access and Pricing
Bart Van Den Daele, Head of External Affairs – Director Market Access - Belux, Gilead Sciences
Mar 2116:30
Conference pass
What patient advocacy can do for you?
Rare Diseases
Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy
Mar 2116:30
Conference pass
Innovative pricing approaches to gene therapy
Advanced Therapies
Lara Pippo, Head Of Market Access, Italy, CSL Behring
Mar 2116:30
Conference pass
Using technology to collect data that makes sense for HTA
Big Data and Digital Health
Vidya Breeveld, Founder, Transmineo
Mar 2116:30
Conference pass
Health data bases versus current practice – gap in information for patients, payers and physicians using Wilson Disease
HTA
Thomas Daniel, Business Development Manager, Vivet Therapeutics
Mar 2116:50
Conference pass
Real World Evidence (RWE) use in practice
Evidence
Sumeet Bakshi, Senior Vice President, Real World Evidence, Lifescience Dynamics
Mar 2116:50
Conference pass
Key trends in Oncology Pricing & Access
Market Access and Pricing
Paolo Correale, Senior Principal, Global Pricing & Access Consulting, EVERSANA
Mar 2116:50
Conference pass
The role of the patient voice in rare disease market access
Rare Diseases
Helen Stoop, Head of Patient Advocacy – Takeda Europe and Canada, Takeda
Mar 2116:50
Conference pass
Collaborative Negotiation at the heart of Pricing and Reimbursement
Advanced Therapies
Stefan Walzer, General Manager, MArS Market Access & Pricing Strategy, Germany
Esther Nzenza, CEO and Founder, DECISIVE CONSULTING LTD
Mar 2116:50
Conference pass
Do we need an HTA framework for artificial intelligence?
Big Data and Digital Health
Rossella Di Bidino, HTA expert, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 2116:50
Conference pass
Price and Revenue management with International Healthcare Providers
HTA
Peter Zimmermann, Sr Director of Global Customer Success, Model N (Switzerland) GmbH
Mar 2117:10
Conference pass
Embracing the organizational move to value-based agreements
Market Access and Pricing
Alison Horsfield, Global Strategy & Innovation Director, AstraZeneca
Mar 2117:10
Conference pass
Payer perspective on how to determine fair price for innovative drugs
Advanced Therapies
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Mar 2117:10
Conference pass
Improving the value of early/surrogate outcome based RCTs for HTA decision making
HTA
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, AstraZeneca
Create your personal agenda –check the favourite icon
Mar 228:55
Conference pass
Chair's Remarks
Keynotes
Ilona Torontali, Global Head Pricing and Reimbursement, Roche
Mar 229:00
Conference pass
Solving the global healthcare inequity gap
Keynotes
Jayasree Iyer, CEO, Access to Medicine Foundation
Mar 229:20
Conference pass
Considerations to reduce disparities between RWE evidence and trial evidence during conditional reimbursement negotiations
Keynotes
Sangeeta Budhia, VP, Pricing & Market Access, Parexel
Mar 229:40
Conference pass
Bridging the Regulatory to Access Gap: Challenges and Opportunities
Keynotes
Gavin Lewis, Global Head of Market Access, Amgen
Mar 2210:00
Conference pass
Bold Access Models for Accelerating Global Health Equity
Keynotes
Amy Israel, Policy and Health Systems Executive, Independent
Shalini Jayasekar Zurn, Senior Advocacy Manager, Union for International Cancer Control
Mar 2211:20
Conference pass
Chair's Remarks
Evidence
Enkeleida Nikai-Fitzgerald, Vice President, Global Real-World Evidence (RWE), Global Commercial Data Science, Janssen Pharmaceutical
Mar 2211:20
Conference pass
Chair's Remarks
Market Access and Pricing
Natasa Zibelnik, Head of Market Access EMEA - Oncology, Menarini Group
Mar 2211:20
Conference pass
Chair's Remarks
Rare Diseases
Toon Digneffe, Head Public Affairs & Public Policy, Takeda
Mar 2211:20
Conference pass
Chair's Remarks
Advanced Therapies
Mar 2211:20
Conference pass
Chair's Remarks
Big Data and Digital Health
Dorothee Bartels, Associate Professor, Hannover medical school
Mar 2211:20
Conference pass
Chair's Remarks
HTA
Yumi Asukai, Senior Director, Gilead Sciences Ltd
Mar 2211:25
Conference pass
Early evidence collection – how early is too early?
Evidence
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Mar 2211:25
Conference pass
Why we must develop a customer centric price perspective
Market Access and Pricing
Giovanny Leon, Global Price Affordability & Early Access Executive Director, Novartis AG
Mar 2211:25
Conference pass
Next steps for the orphan medicines regulation review
Rare Diseases
Thomas Bols, Head of Government Affairs and Patient Advocacy, PTC Therapeutics
Mar 2211:25
Conference pass
Access to gene therapies – challenges, opportunities, and learnings
Advanced Therapies
Gunter Harms, Senior Market Access Director, Novartis Gene Therapies
Mar 2211:25
Conference pass
Innovating user experience in digital health
Big Data and Digital Health
Fausto Artico, Global R&D Tech Head of Innovation & Data Science, GSK
Mar 2211:25
Conference pass
Real-World Evidence: where are we at in HTA submissions for Orphan Drugs? Are there new opportunities?
HTA
Helene Chevrou-Severac, HEOR RWE Centre of Excellence Head, International & Japan, Alexion – AstraZeneca Rare Disease
Mar 2211:45
Conference pass
Evidence Generation for early-stage assets
Evidence
Teddy Sun, Evidence Generation Lead, Takeda
Mar 2211:45
Conference pass
Data, the Currency that defines product value (We need to get it right!)
Market Access and Pricing
Luca Dellamano, Director Market Access, Fingerpost Consulting
Edward Stockton, Senior Director: Market Access, Fingerpost Consulting
Mar 2211:45
Conference pass
Addressing the pricing challenge with low-cost and off-label comparators in rare diseases
Rare Diseases
Richard Sear, Director, Dolon
Mar 2211:45
Conference pass
Sustainable access to ATMPs in non-rare indications
Advanced Therapies
Christel Jansen, Director, Inbeeo
Maximus Rex, Manager, Inbeeo
Mar 2211:45
Conference pass
Digital Health – external promises versus internal challenges
Big Data and Digital Health
Fausto Artico, Global R&D Tech Head of Innovation & Data Science, GSK
Dorothee Bartels, Associate Professor, Hannover medical school
Jesper Bjerggren, European Market Access Lead Respiratory/Digital Health, TEVA pharmaceuticals
Mar 2211:45
Conference pass
A Comparison of Digital Health Technologies policies, Health Technology Assessments, and reimbursement practices in France, Germany, and the UK
HTA
Mar 2212:05
Conference pass
Can we afford a cure? -a payers perspective value based contracting with innovative medicines
Market Access and Pricing
Omar Ali, Visiting Lecturer, University of Portsmouth
Mar 2212:05
Conference pass
Management of Advanced Therapies – challenges and solutions as seen by payers, employers and providers
Advanced Therapies
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Mar 2212:05
Conference pass
HTA Challenges with combination products – the future of combination branded products
HTA
Lara J Wolfson, Executive Director and Head of Hta Statistics, Merck
Mar 2212:25
Conference pass
From zero to hero: The path to take predictive pricing decisions
Market Access and Pricing
Mar 2212:25
Conference pass
Are payer archetypes still relevant in 2023?
HTA
Francesca Torelli, Associate Director, Valid Insight
Mar 2213:55
Conference pass
Roundtables
Keynotes
Roundtable 01: HTA methods for ATMP’s
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Roundtable 02: New EU HTA regulation (HTAR) from 2025 – Countries preparedness & practical implications.
Zinajda Zolic-Karlsson, Senior advisor, Norwegian medicines agency
Roundtable 03: Improving treatment guidelines for sickle cell anaemia
Augusta Elizabeth Koroma, Chief Executive Officer, Sickle cell Intervention U.K
Roundtable 04: Risk-sharing agreements – what works and what doesn’t?
Ariella Toren, Director Of Medicine And Medical Technologies, Hmos Department, Israel - Ministry Of Health
Tal Morginstin, Director, HTA division, Ministry of Health
Roundtable 05: Healthcare Innovation and Financial Sustainability
Huib Kooijman, Advisor, EQRx, Inc.
Vanessa Mirsky, Senior Director of Corporate Strategy and Global Payer Partnerships, EQRx, Inc.
Roundtable 06: Payer Evidence Frameworks on Digital Health
Zsombor Zrubka, Associate Professor - Department Of Health Economics, Obuda University
Roundtable 07: How to overcome challenges in access to personalised medicines/precision oncology
Marisca Marian, Market Access Strategy Leader, Bayer
Roundtable 08: Harmonising off-label use in oncology: access and evidence
Marnix Artz, Head of Patient Access, Pricing & Public Affairs, Netherlands, Merck Group
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, CZ
Roundtable 09: Innovation in Market Access – how do we have to develop?
Birgit Holz, Global Head of Contracting Innovation, Sanofi
Roundtable 10: The challenges around equal patient access to molecular diagnostics
Silvia van der Flier, Medical Advisor, VGZ
Roundtable 12: Data Strategies
Enkeleida Nikai-Fitzgerald, Vice President, Global Real-World Evidence (RWE), Global Commercial Data Science, Janssen Pharmaceutical
Roundtable 13: The CDx conundrum
Rachele Saccon, Engagement Manager, Lifescience Dynamics Ltd
Maeva Bavoux, Consultant, Lifescience Dynamics
Alberto Briones, Senior Consultant, Lifescience Dynamics
Roundtable 14: Patient Experience Data: 3 Reasons Why You Can't Afford To Ignore It!
Roundtable 15: The role of digital and AI: where do they add value? how quickly will they be adopted? how far should these be part of evidence and access plans?
Richard Tolley, Head of Market Access EU, Ipsos Market Access
Mar 2214:50
Conference pass
Chair's Remarks
Evidence
Maartje Smulders, Sr Director RWE, Astellas
Mar 2214:50
Conference pass
Chair's Remarks
Market Access and Pricing
Sam Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Mar 2214:50
Conference pass
Chair's Remarks
Rare Diseases
Gina Ewy, VP, Head of Global Market Access, Hansa Biopharma
Mar 2214:50
Conference pass
Chair's Remarks
Advanced Therapies
Stephen Connell, Director Payer Insights & Access, Pfizer Ltd
Mar 2214:50
Conference pass
Chair's Remarks
Big Data and Digital Health
Jesper Bjerggren, European Market Access Lead Respiratory/Digital Health, TEVA pharmaceuticals
Mar 2214:50
Conference pass
Chair's Remarks
HTA
Ramiro Gilardino, Global HTA & Access Policy Lead, MSD
Mar 2214:55
Conference pass
Evidence generation and interpretation for rare disease
Evidence
Alicia Granados, Head, Global Rare Diseases Scientific Advocacy, SANOFI
Mar 2214:55
Conference pass
Dos and don'ts of analogue analysis
Market Access and Pricing
Shri Mukku, Founding Director, Access Infinity Ltd
Mar 2214:55
Conference pass
Price and Reimbursement challenges for orphan drugs in Europe
Rare Diseases
Gael Le Rouzo, Global market access director, EUSA Pharma
Mar 2214:55
Conference pass
Point of care manufacturing of cell and gene therapies – Access, Business Model and Regulatory Challenges
Advanced Therapies
Peter Takacs, Global Business Operations, Miltenyi Biotec B.V. & Co. KG
Mar 2214:55
Conference pass
Citizen engagement in the use of health data analytics
Big Data and Digital Health
James Maddocks, International Policy Advisor, NHS Confederation
Mar 2214:55
Conference pass
Lessons learned from joint HTA processes
HTA
Andrew Olaye, Head of EMEA Market Access, Orchard Therapeutics Ltd
Mar 2215:15
Conference pass
Patient Perspective in Real-World Evidence: from Dream to Reality
Evidence
Paci Sandra, Head access europe, Argenx
Mar 2215:15
Conference pass
The Good, The Bad, & The Ugly of Value Messaging: Impact of Testing & Validation
Market Access and Pricing
Saad Ahmad, Director of New Business Development, Global Pricing, and Market Access, Market Access Solutions LLC.
Sandip Shah, Chief Executive Officer, MKTXS
Mar 2215:15
Conference pass
Keeping up with rapid innovation: how technology is solving the orphan drugs pricing problem
Rare Diseases
Mar 2215:15
Conference pass
Patient access – treatments and information
Advanced Therapies
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.
Mar 2215:15
Conference pass
‘Need for standardisation of quality-of-life measurements in cancer trials’
Big Data and Digital Health
Susanne Osanto, Professor of Oncology, Lumc
Mar 2215:15
Conference pass
Recent developments in the Dutch reimbursement pathway: Impact of the ‘de sluis’ (lock chamber) 8 years later
HTA
Mar 2215:35
Conference pass
Supporting the impact of Biosimilars through Biosimilar Public procurement in European tenders
Market Access and Pricing
Sandra Pisek, Head Established Products, Europe, Sandoz
Mar 2215:35
Conference pass
The Canadian Landscape for Expensive Drugs for Rare Diseases
Rare Diseases
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Mar 2215:35
Conference pass
How to tackle the emerging outcomes demonstration / cost management challenge in different markets in launch planning
HTA
Michael Epstein, Head, Pricing and Commercial Strategy, Ascenian Consulting and Market Research, LLC
Susanne Michel, Head, HTA Consulting and Evidence Planning, Ascenian Consulting and Market Research, LLC
Mar 2216:25
Conference pass
Chair's Remarks
Evidence
Birgit Holz, Global Head of Contracting Innovation, Sanofi
Mar 2216:25
Conference pass
Chair's Remarks
Market Access and Pricing
Grace Wayi-Wayi, Global Associate Director - Market Access, Eusa
Mar 2216:25
Conference pass
Chair's Remarks
Rare Diseases
Ana Palma, Senior Director Global Head of Patient Access & Access Policy, Sobi
Mar 2216:25
Conference pass
Chair's Remarks
Big Data and Digital Health
Rasha Mokaddem, Market Access Director, Johnson & Johnson
Mar 2216:30
Conference pass
HTA for orphan drugs and the use of real world data in Germany
Evidence
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Mar 2216:30
Conference pass
Risk Sharing Agreements
Market Access and Pricing
Marta Pastor, Economic Senior Consultant, Catalan Health Service
Mar 2216:30
Conference pass
The challenge of delivering innovation for ultra-rare diseases
Rare Diseases
Jan Swiderski, Public Affairs & Advocacy Director, IPSEN
Mar 2216:30
Conference pass
Patient pathways for medical devices and policy considerations
Big Data and Digital Health
Aleksandra Krygiel-Nael, Head of Government Affairs and Policy, Medical Devices, Johnson & Johnson
Mar 2216:50
Conference pass
Will the treatment work for me?
Evidence
Stefan Franzen, Director, Medical & Payer Evidence Statistics, Astrazeneca
Mar 2216:50
Conference pass
The role of AI and data as accelerators in the Tender Management process
Market Access and Pricing
Mar 2216:50
Conference pass
The sustainability of rare disease treatment
Rare Diseases
Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy
Ana Palma, Senior Director Global Head of Patient Access & Access Policy, Sobi
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Jan Swiderski, Public Affairs & Advocacy Director, IPSEN
Create your personal agenda –check the favourite icon
Mar 238:55
Conference pass
Chair's Remarks
Keynotes
Daniel Jackson, Global Head of Market Access Policy, UCB
Mar 239:00
Conference pass
Market access and pricing policy changes and how we navigate them
Keynotes
Timothy Lenehan, CVP Global Evidence, Pricing and Access, Novo Nordisk
Mar 239:20
Conference pass
Unlocking the power of social listening: a critical role in early value assessments
Keynotes
James Wright, Director, Valid Insight
Mar 239:40
Conference pass
National implementation of the HTA regulation: example and feedback from the French National Authority for health
Keynotes
Fabienne Bartoli, Director-General, French National Authority for Health
Mar 2310:00
Conference pass
3 Industries are converging into 1: are you ready for the challenges ahead?
Keynotes
Andrea Mantovani, Vice President - Global Market Access & Pricing, Alira Health
Ahmad Bechara, Senior Vice President Global Market Access and Pricing, Alira Health
Mar 2311:40
Conference pass
Chair's Remarks
Evidence
Fleur Pool, Medical Access Manager, Novartis Pharma B.V. NL
Mar 2311:40
Conference pass
Chair's Remarks
Market Access and Pricing
Laurene Redding, Head, Value, Access & Policy, Canada, BeiGene
Mar 2311:40
Conference pass
Chair's Remarks
Rare Diseases
Luigi Angelillo, Director, Market Access EMEA, Argenx
Mar 2311:45
Conference pass
Patient engagement in the Israeli HTA process
Evidence
Tal Morginstin, Director, HTA division, Ministry of Health
Mar 2311:45
Conference pass
Managed Agreements vs. Product Profile: Who Gets What, and Why?
Market Access and Pricing
Ayman Semaan, Market Access & Pricing Lead, Biologix and Director of Communication - ISPOR Lebanon Chapter, BIOLOGIX
Mar 2311:45
Conference pass
Are early access programs possible in ultra-rare acute diseases requiring urgent treatment? Part 1
Rare Diseases
Jelle Kleijn, Global Head of Acanthamoeba Keratitis, SiFi
Mar 2312:05
Conference pass
The Israeli Healthcare Market Landscape
Market Access and Pricing
Tomer Ben Zaken, Head of Sick Funds Access, AbbVie
Mar 2312:05
Conference pass
Are early access programs possible in ultra-rare acute diseases requiring urgent treatment? Part 2
Rare Diseases
Luca Tofani, Director, Pricing and MArket Access, SIFI spa
Mar 2312:05
Conference pass
Are early access programs possible in ultra-rare acute diseases requiring urgent treatment? Part 2
Rare Diseases
Luca Tofani, Director, Pricing and MArket Access, SIFI spa
Mar 2312:25
Conference pass
Quantifying the future burden of disease: generating evidence to inform and empower decision-makers, a case study with AstraZeneca
Evidence
Mar 2312:25
Conference pass
Striking the right balance: How to use game theory to support strategic pricing
Market Access and Pricing
Mar 2312:25
Conference pass
How to drive the policy agenda to speed up diagnosis for rare disease patients?
Rare Diseases
Stefaan Fiers, Head of Corporate Communication, Public Affairs & Patient Advocacy, Belgium, Takeda
Mar 2313:45
Conference pass
Roundtables
Keynotes
Roundtable 01: Best fitting care for specialty care medicines
Nick Besseling, Manager Value Strategies & Agreements, Astrazeneca
Roundtable 02: RWE – what good looks like
Mercedes Romano Rodriguez, Senior Global Market Access Manager, ALK
Roundtable 03: How to Tango? Challenges of Public-Private Partnerships
Frederik Mortensen, Head of Market Access, Novartis Oncology Netherlands, Novartis
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Roundtable 04: What is true patient centred healthcare? Alignment of patients and pharma within patient centred healthcare/shared decision making
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Roundtable 05: How emerging technologies will revolutionise your business modelling
Fausto Artico, Global R&D Tech Head of Innovation & Data Science, GSK
last published: 20/Mar/23 09:25 GMT
Get Involved
To Sponsor Or Exhibit
David Boore
david.boore@terrapinn.com
+44 20 8164 3052
To Speak
Francesca Wiggins
francesca.wiggins@terrapinn.com
Marketing Opportunities
Diana Cobzac
diana.cobzac@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events